1st Counsel – Lifestyle
Author:
IGC Pharma, Inc.
IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase
April 28, 2026
IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion
April 22, 2026
IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout
April 14, 2026
Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts
April 8, 2026
IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025
March 19, 2026
IGC Pharma to Showcase AI Platform with Alzheimer’s Disease Data Initiative at ADPD 2026
March 18, 2026